Bedrijfsoverzicht
PMGC Holdings Inc. is a biopharmaceutical entity dedicated to the development and strategic acquisition of innovative aesthetic medicines and therapeutic products designed to address significant health challenges. Operating within the Healthcare sector and specifically the Biotechnology industry, the company focuses on its lead product, EL-22, which represents a first-in-class engineered probiotic approach aimed at mitigating obesity while preserving muscle mass. The organization employs a workforce of 32 individuals to execute its research and development initiatives, reflecting a lean operational structure typical of early-stage biotech firms. With a market capitalization of $9.28M and annual revenue of $590,084, the company's valuation indicates a small-cap status where market value significantly exceeds current sales generation, suggesting that investors are pricing in future potential rather than current profitability. This disparity between market cap and revenue highlights the high-risk, high-reward nature of the biotechnology sector, where capital is allocated based on pipeline assets and long-term therapeutic goals rather than immediate earnings performance.
Financiële gezondheid
The company reported revenue of $590,084 over the trailing twelve months, yet it posted a net income of -$7,780,740, revealing a substantial gap that underscores an aggressive cost structure or significant investment in research and development activities that currently outpace revenue generation. EBITDA stood at -$7,026,714, indicating that even before interest, taxes, depreciation, and amortization, the core operations are operating at a loss, which is common for biotech firms in the development phase. Free cash flow was recorded at -$2,762,601, meaning the company is consuming cash reserves to fund its operations and product development, thereby limiting its immediate financial flexibility without external capital injections. The gross margin stands at -174.9%, the operating margin at -945.0%, and the profit margin at 0.0%, collectively illustrating a financial profile where costs far exceed revenues and the company has not yet achieved profitability on its sales. Total cash holdings of $6.07M provide a buffer against total debt of $2.64M, but the debt-to-equity ratio of 33.75 suggests a leveraged balance sheet relative to the equity base. The current ratio of 1.74 indicates that the company holds sufficient current assets to cover its short-term liabilities, pointing to a manageable level of short-term liquidity despite the overall financial losses. Return on Equity is -107.3% and Return on Assets is -40.7%, metrics that reveal management is currently utilizing shareholder and asset bases to generate negative returns, a typical characteristic of companies in the pre-revenue or early commercialization stage of their lifecycle.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of earnings, implying that traditional earnings-based valuation models are not applicable and that the market is relying on alternative metrics to assess value. The price-to-book ratio is 0.05, indicating that the market values the company at only 5% of its book value, which suggests a significant discount relative to the assets recorded on the balance sheet. The price-to-sales ratio is 15.72 and the EV/EBITDA is -0.30, metrics that suggest the market is willing to pay a high multiple for sales in hopes of a future turnaround or successful product launch, while the negative EV/EBITDA confirms the company's current unprofitability. The stock has traded between a 52-week low of $1.62 and a 52-week high of $309.89, representing an extreme volatility range where the current price dynamics must be evaluated against this wide historical spread. The beta value is 0.71, which indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings despite its high valuation multiple relative to sales.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the lack of historical comparative data or the transition period where consistent year-over-year growth metrics have not yet been established. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests any available resources or future earnings directly back into research, development, and business expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies that prioritize pipeline development and clinical trial funding over providing income streams to investors. The overall growth and income profile is characterized by a complete absence of current earnings generation, a high price-to-sales multiple relative to revenue, and a reliance on cash reserves to sustain operations until a product reaches commercial viability.